Zai Lab Obtains Breakthrough Therapy Designation For Efgartigimod Alfa Injection In Patients With Chronic Inflammatory Demyelinating Polyneuropathy In China
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa